ဤအပိုင်းအကြောင်း
In this episode of Corruption, Crime and Compliance, Michael Volkov examines the FTC's October 5, 2026 warning letters to 24 of the nation's largest healthcare services companies, which assert that failing to provide timely, accurate, and complete pricing, particularly for scheduled, non-emergency care, can be a deceptive or unfair practice under Section 5 of the FTC Act, and that incomplete disclosures omitting physician or facility fees can mislead patients into believing they have been told the total cost. He highlights the letters' most consequential point, that CMS price transparency rules are only a regulatory floor and provide no safe harbor from FTC liability, and places the action in context alongside tougher CMS enforcement, the No Surprises Act good faith estimate, the FTC's new Healthcare Task Force, and Chairman Ferguson's warning that investigations are already open. Volkov closes with a practical review plan: map every channel where patients receive prices, mystery-shop quotes against final bills, close the professional fee gap, tighten the language of estimates, bring consumer protection into price transparency governance, and document corrective action.
